Comment on: Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry: reply

Rheumatology (Oxford). 2020 Aug 1;59(8):2181-2182. doi: 10.1093/rheumatology/keaa160.
No abstract available

Publication types

  • Comment

MeSH terms

  • Arthritis, Rheumatoid* / complications
  • Arthritis, Rheumatoid* / drug therapy
  • Disease Progression
  • Humans
  • Lung Diseases, Interstitial* / drug therapy
  • Lung Diseases, Interstitial* / etiology
  • Registries
  • Rituximab / therapeutic use

Substances

  • Rituximab